SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk human papillomavirus infection. High-income countries that have implemented human papillomavirus (HPV) vaccination and screening programs have...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2024-11, Vol.26 (11), p.2771-2782
Main Authors: Manso, Luis, Ramchandani-Vaswani, Avinash, Romero, Ignacio, Sánchez-Lorenzo, Luisa, Bermejo-Pérez, María José, Estévez-García, Purificación, Fariña-Madrid, Lorena, García García, Yolanda, Gil-Martin, Marta, Quindós, María
Format: Article
Language:English
Subjects:
Chemoradiotherapy
Clinical Guides in Oncology
Female
Humans
Immunotherapy - methods
Medical Oncology - standards
Medicine
Medicine & Public Health
Neoplasm Staging
Oncology
Papillomavirus Infections - complications
Papillomavirus Infections - therapy
Papillomavirus Vaccines - administration & dosage
Papillomavirus Vaccines - therapeutic use
Societies, Medical
Uterine Cervical Neoplasms - diagnosis
Uterine Cervical Neoplasms - therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk human papillomavirus infection. High-income countries that have implemented human papillomavirus (HPV) vaccination and screening programs have seen dramatic reductions in CC incidence, while developing countries where these programs are not available continue to experience high rates of CC deaths. In early-stage CC, the primary treatment is surgery or radiotherapy, whereas concurrent chemo-radiotherapy (CRT) remains the conventional approach in locally advanced stages until the upcoming approval of immunotherapy. The incorporation of immunotherapy in combination with chemotherapy (with or without bevacizumab) in first line and as monotherapy in second line after platinum-based chemotherapy, has significantly increased overall survival (OS) in recurrent or metastatic CC. The purpose of this guideline is to summarize the most relevant evidence in the diagnosis, treatment, and follow-up of CC and to provide evidence-based recommendations for clinical practice.
ISSN:1699-3055
1699-048X
1699-3055
DOI:10.1007/s12094-024-03604-3